Close Menu

NEW YORK – Enzo Biochem reported after the close of the market on Tuesday that its fiscal fourth quarter revenues fell 8 percent year over year, reflecting new, "sharply lower" industry-wide reimbursement rates under the Protecting Access to Medicare Act (PAMA).

For the three months ended July 31, the diagnostics company said total revenues sank to $20.9 million from $22.8 million a year earlier.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.